Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection

RevImmune’s goal is to successfully trial CYT107 on COVID-19 patients as part of a global effort to treat the disease. They believe IL-7 (CYT107) can prevent patients who are in the hospital for COVID-19 from progressing to having to be treated in the ICU.